SecBot SecBot
SECBOTREPLAY Home › Report › TNGX

TNGX · Tango Therapeutics reported Q2 2026 net loss of $0.37 per share,…

Tango Therapeutics, Inc. · PRESS-RELEASE filed Aug 11, 2026 at 07:00 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Aug 11, 2026 at 07:00 ET

Tango Therapeutics reported Q2 2026 net loss of $0.37 per share, slightly wider than the $0.35 loss in Q2 2025, with zero collaboration revenue as the Gilead deal concluded. The key catalyst is the 92% objective response rate for vopimetostat plus daraxonrasib in MTAP-deleted pancreatic cancer, driving plans for a Phase 3 trial and a $1.0B cash runway through commercialization. The stock's move hinges on the ESMO data presentation and Phase 3 design finalization in 2H 2026, not the financial results themselves.

  • Net loss of $55.3M ($0.37/share) for Q2 2026 vs $38.9M ($0.35/share) in Q2 2025
  • Cash position of $1.0B as of June 30, 2026, expected to fund current operating plan
  • Vopimetostat + daraxonrasib achieved 92% objective response rate and 90% six-month PFS in MTAP-deleted, RAS-mutant pancreatic cancer
  • Company initiating dialogue with regulators for registrational path; Phase 3 trial design to be finalized in 2H 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access